US2021054354A1PendingUtilityA1

Rationally-designed single-chain meganucleases with non-palindromic recognition sequences

Assignee: PREC BIOSCIENCES INCPriority: Oct 31, 2007Filed: Oct 23, 2020Published: Feb 25, 2021
Est. expiryOct 31, 2027(~1.2 yrs left)· nominal 20-yr term from priority
C12N 9/22C12N 15/8509C12N 15/902C12Y 301/04C12N 9/16A61P 43/00C12Y 301/00A61P 31/00A61P 31/12C12N 2800/80A61P 33/02A61P 31/04C12N 15/907
77
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are rationally-designed, non-naturally-occurring meganucleases in which a pair of enzyme subunits having specificity for different recognition sequence half-sites are joined into a single polypeptide to form a functional heterodimer with a non-palindromic recognition sequence. The invention also relates to methods of producing such meganucleases, and methods of producing recombinant nucleic acids and organisms using such meganucleases.

Claims

exact text as granted — not AI-modified
1 .- 9 . (canceled) 
     
     
         10 . A recombinant single-chain meganuclease comprising:
 a first LAGLIDADG subunit derived from a first mono-LAGLIDADG meganuclease, said first LAGLIDADG subunit having a first recognition half-site;   a second LAGLIDADG subunit derived from a second mono-LAGLIDADG meganuclease or a di-LAGLIDADG meganuclease, said second LAGLIDADG subunit having a second recognition half-site;   wherein said first and second LAGLIDADG subunits are covalently joined by a polypeptide linker such that said first LAGLIDADG domain is N-terminal to said linker and said second LAGLIDADG domain is C-terminal to said linker; and   wherein said first and second LAGLIDADG subunits are capable of functioning together to recognize and cleave a non-palindromic DNA sequence which is a hybrid of said first recognition half-site and said second recognition half-site.   
     
     
         11 . The recombinant single-chain meganuclease of  claim 10  wherein:
 the first LAGLIDADG subunit is derived from a mono-LAGLIDADG meganuclease selected from the group consisting of I-Crel, I-Msol and I-Ceul; and 
 the second LAGLIDADG subunit is derived from either (1) a mono-LAGLIDADG meganuclease selected from the group consisting of I-Crel, I-Msol and I-Ceul, or (2) a di-LAGLIDADG meganuclease selected from the group consisting of I-Dmol, I-Scel and I-Anil. 
 
     
     
         12 . The recombinant single-chain meganuclease of  claim 10  wherein:
 the first LAGLIDADG subunit is derived from a different species than the second LAGLIDADG subunit. 
 
     
     
         13 . The recombinant single-chain meganuclease of  claim 10  wherein:
 said first LAGLIDADG subunit comprises a polypeptide sequence having at least 85% sequence identity to a first LAGLIDADG domain selected from the group consisting of residues 9-151 of a wild-type I-Crel meganuclease of SEQ ID NO: 1; residues 11-162 of a wild-type I-Msol meganuclease of SEQ ID NO: 2; and residues 55-210 of a wild-type I-Ceul meganuclease of SEQ ID NO: 3. 
 
     
     
         14 . The recombinant single-chain meganuclease of  claim 11  wherein:
 said second LAGLIDADG subunit comprises a polypeptide sequence having at least 85% sequence identity to a second LAGLIDADG domain selected from the group consisting of residues 9-151 of a wild-type I-Crel meganuclease of SEQ ID NO: 1; residues 11-162 of a wild-type I-Msol meganuclease of SEQ ID NO: 2; residues 55-210 of a wild-type I-Ceul meganuclease of SEQ ID NO: 3; residues 9-96 of a wild-type I-Dmol of SEQ ID NO: 4; residues 105-178 of a wild-type I-Dmol of SEQ ID NO: 4; residues 32-123 of a wild-type I-Scel of SEQ ID NO: 5; residues 134-225 of a wild-type I-Scel of SEQ ID NO: 5; residues 4-121 of a wild-type I-Anil of SEQ ID NO: 6; and residues 136-254 of a wild-type I-Anil of SEQ ID NO: 6. 
 
     
     
         15 . The recombinant single-chain meganuclease of  claim 11  wherein:
 each of said LAGLIDADG subunits comprises at least 85% identity to a LAGLIDADG domain independently selected from the group consisting of residues 9-151 of a wild-type I-Crel meganuclease of SEQ ID NO: 1; residues 11-162 of a wild-type I-Msol meganuclease of SEQ ID NO: 2; residues 55-210 of a wild-type I-Ceul meganuclease of SEQ ID NO: 3; residues 9-96 of a wild-type I-Dmol of SEQ ID NO: 4; residues 105-178 of a wild-type I-Dmol of SEQ ID NO: 4; residues 32-123 of a wild-type I-Scel of SEQ ID NO: 5; residues 134-225 of a wild-type I-Scel of SEQ ID NO: 5; residues 4-121 of a wild-type I-Anil of SEQ ID NO: 6; and residues 136-254 of a wild-type I-Anil of SEQ ID NO: 6; and 
 at least one of said LAGLIDADG domains comprises at least one amino acid modification disclosed in any of Tables 11, 12, 13 and 14. 
 
     
     
         16 . The recombinant single-chain meganuclease of  claim 15  wherein:
 at least one LAGLIDADG domain is derived from I-Crel and at least one modification is selected from Table 1 of any of Tables 11, 12, 13 and 14; 
 at least one LAGLIDADG domain is derived from I-Msol and at least one modification is selected from Table 12; 
 at least one LAGLIDADG domain is derived from I-Ceul and at least one modification is selected from Table 13; or 
 at least one LAGLIDADG domain is derived from I-Scel and at least one modification is selected from Table 14. 
 
     
     
         17 . The recombinant single-chain meganuclease of  claim 11  wherein:
 each of said LAGLIDADG subunits has a recognition half-site selected from the group consisting of SEQ ID NOs: 7-30. 
 
     
     
         18 . The recombinant single-chain meganuclease of  claim 17  wherein:
 at least one of said LAGLIDADG subunits has a recognition half-site selected from the group consisting of SEQ ID NOs: 7-30; and 
 the other of said LAGLIDADG subunits has a recognition half-site which differs by at modification of at least one base pair from a recognition half-site selected from the group consisting of SEQ ID NOs: 7-30. 
 
     
     
         19 . The recombinant single-chain meganuclease of  claim 10  wherein:
 said polypeptide linker is a flexible linker. 
 
     
     
         20 . The recombinant single-chain meganuclease of  claim 19  wherein:
 said linker comprises 15-40 residues. 
 
     
     
         21 . The recombinant single-chain meganuclease of  claim 19  wherein:
 said linker comprises 25-31 residues. 
 
     
     
         22 . The recombinant single-chain meganuclease of  claim 19  wherein:
 at least 50% of said linker comprises polar uncharged residues. 
 
     
     
         23 . The recombinant single-chain meganuclease of  claim 10  wherein:
 said polypeptide linker has a stable secondary structure. 
 
     
     
         24 . The recombinant single-chain meganuclease of  claim 23  wherein:
 said stable secondary structure comprises at least two α-helix structures. 
 
     
     
         25 . The recombinant single-chain meganuclease of  claim 23  wherein:
 said stable secondary structure comprises from N-terminus to C-terminus a first loop, a first α-helix, a first turn, a second α-helix, and a second loop. 
 
     
     
         26 . The recombinant single-chain meganuclease of  claim 23  wherein:
 said linker comprises 23-56 residues.

Join the waitlist — get patent alerts

Track US2021054354A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.